Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Gains from Sales and Divestitures (2017 - 2025)

Harvard Bioscience (HBIO) has disclosed Gains from Sales and Divestitures for 9 consecutive years, with $536145.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Sales and Divestitures changed N/A to $536145.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $536145.0, a N/A change, with the full-year FY2024 number at $717119.0, up 126.79% from a year prior.
  • Gains from Sales and Divestitures was $536145.0 for Q3 2025 at Harvard Bioscience, up from $442448.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $1.2 million in Q4 2021 to a low of $115976.0 in Q3 2023.
  • A 5-year average of $450100.5 and a median of $401308.0 in 2022 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: crashed 70.95% in 2022, then surged 126.79% in 2024.
  • Harvard Bioscience's Gains from Sales and Divestitures stood at $1.2 million in 2021, then crashed by 65.63% to $401308.0 in 2022, then decreased by 21.21% to $316210.0 in 2023, then soared by 126.79% to $717119.0 in 2024, then dropped by 25.24% to $536145.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Gains from Sales and Divestitures are $536145.0 (Q3 2025), $442448.0 (Q2 2025), and $717119.0 (Q4 2024).